3 February 2022PatentsAlex Baldwin

Hirshfeld defends IPR review authority under Arthrex

The acting director of the US Patent and Trademark Office (USPTO) Andrew Hirshfeld has defended his right to review final Patent Trial and Appeal Board (PTAB) decisions under Arthrex.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Patents

Drew Hirshfeld: boosting quality and quantity at the USPTO

26 February 2018 Despite concerns over patent quality and with at least one rising backlog, there are positives for the USPTO to focus on, as commissioner for patents Drew Hirshfeld tells WIPR.

Patents

Hirshfeld grants first USPTO director review after Arthrex

4 November 2021 The acting director of the US Patent and Trademark Office Drew Hirshfeld has agreed for the first time to review a final written decision from the Patent Trial and Appeal Board (PTAB) after being given oversight over the board’s rulings in the Supreme Court’s Arthrex decision.

On our radar...

Philip Morris case triggers AIPPI call for EPO action

Penn State prevails in trademark dispute with Vintage Brand over retro logos

Google: Ex-engineer ‘touted dominion over the trade secrets he stole’

‘Trade secrets can be emotional’: Seth Gerber, Morgan Lewis

Private equity eyes controlling interest in Anaqua

Motorola can’t enforce ‘multiple’ US Hytera damages in UK

UK firms Venner Shipley and AA Thornton combine

Hirshfeld defends IPR review authority under Arthrex

More on this story

Editor's picks

Editor's picks

More articles